logo
The world's best-preserved fossils are right outside Chicago. But there are no dinosaur bones at Mazon Creek

The world's best-preserved fossils are right outside Chicago. But there are no dinosaur bones at Mazon Creek

Yahoo27-05-2025
CHICAGO — Sixty-five miles southwest of Chicago, a small hill that looks like a prop from an Indiana Jones movie breaks up the flat, monotone landscape. Consisting of shale, sandstone and rocks from an old coal mine, the waste pile — located on a massive river delta from another era — is an unremarkable remnant from the region's once-thriving coal industry.
Except it contains many of the world's best-preserved, most diverse fossils.
The defunct mine's location in Grundy County is one of several sites spanning six counties that belong to the Mazon Creek fossil beds, a time capsule dating back some 309 million years — way before the age of dinosaurs — to the Carboniferous period, when large coal deposits formed around the world and terrestrial ecosystems developed. At the time, this area was swampy and tropical, and home to various organisms like the Illinois state fossil, the peculiar Tully monster, which has been found only here — a cigar-shaped vertebrate creature up to a foot long with eyes that protruded sideways, a long snout and a toothy mouth.
'You get everything from insects, millipedes, plants, jellyfish, all the way to early tetrapods, big animals like embolomeri, as well as larval forms,' said Arjan Mann, who recently joined the museum as an assistant curator of fossil fishes and early tetrapods, or four-limbed animals, such as the crocodile-like and predatory embolomeri. 'This makes Mazon Creek the most complete record of a Paleozoic ecosystem' — an era that contained six periods and spanned from 541 million to 252 million years ago.
Despite their uniqueness, these sites remain relatively unknown to many outside paleontology circles. Maybe because no dinosaur bones have ever been found in this area or the rest of Illinois, and those tend to draw the most attention.
Even as the Field Museum celebrates on Friday 25 years since the arrival of famed Sue the T. rex to its halls after the bones were discovered in South Dakota, some scientists are shining a light on other creatures and plants that once roamed and grew in Illinois.
Mann's role as a paleontologist, specifically at the Field Museum, was recently ranked the second-coolest job in the country on a career.io survey. And he wants to make the science more accessible, regardless of age or expertise, by collaborating with amateur fossil collectors from the Earth Science Club of Northern Illinois to find new specimens.
The club and museum take amateur fossil hunters to Mazon Creek sites on public land like state parks, where permits are required, as well as on private property like the Grundy County site they recently visited where they have an established relationship with the landowners.
In 1946, the museum hired Eugene Richardson as curator of fossil invertebrates, and he became a strong advocate for collaborating with amateur fossil collectors in Mazon Creek localities. Since Richardson's death in 1983, paleontological research at the institution has skewed toward dinosaurs, Mann said. Now, he wants to renew the museum's focus on Mazon Creek.
'I did my dissertation entirely on this site, even though I'm from Canada,' Mann said. 'So my love for this site and my knowledge of what it was in the past, gives me a drive to want to revitalize both the scientific research to show how important the locality is, (and) how important it is as a social experiment — and how we can involve people at all levels.'
Rich Holm, a software engineer, joined the club about 20 years ago with his daughter, Anna. While picking through the pea gravel in their Naperville backyard, she'd found tiny fossils of a now-extinct, horn-shaped coral and a brachiopod — a marine animal that resembles a clam. A visit to a gift shop that sold stones and crystals solidified Anna's interest and she told Holm she wanted to collect rocks.
'I said, 'Sure, that's fine,'' he recalled. Which is how he ended up on the club's website and began taking her to junior group outings. 'Now I'm on the board of directors.'
Holm said the paleontology experiences fostered a love for science in Anna, who went on to study microbiology in college. Sometimes she'll join him on one of his 20 to 40 yearly collecting field trips. On one trip, he found a fossilized Paleocampa anthrax , a rare, extinct worm with bristles that make it look like a caterpillar and is related to modern-day fireworms. He has also found a fossilized tailless whip scorpion, of the extinct species Graeophonus carbonatius; arachnids like this are rare and coveted among collectors.
But acquiring rare specimens requires patience and identifying a lot of concretions, or mineral masses that sometimes contain fossils. The shape of a concretion generally offers a clue into what's inside, so collectors want to bring back as many as possible to open, Holm said.
At the recent Mazon Creek dig, participants used pickaxes to sift through the waste pile, known as a spoil tip.
'Can I give you some of the stuff in my pocket?' Mann asked a colleague as he stood on top of the spoil tip. 'It's weighing me down.'
In a comical scene, he started pulling out rock after rock. 'You just keep getting them,' Mann laughed.
'And it's like a second collection experience when you open them,' he said. 'These act as little time capsules that entomb animals within them.'
Holm has found so many fossils that he often gives them away to family, friends and even co-workers, who proudly display the gifts on their desks.
'You can get buried' in a collection, he joked. 'So I give them away quite readily.'
While some prefer to crack the concretions with a hammer for faster results, this can damage the fossil inside. Experts suggest opening the Mazon Creek stones by alternately freezing and thawing them in water. As the liquid freezes and expands, it gently cracks the rocks open by putting pressure on their weakest points.
This method often requires that collectors' families make room for the fossils at home.
'It's a passion that just grows exponentially,' Holm said. 'So, probably very soon after you start, you need a freezer of your own.'
For Father's Day one year, Holm's wife gave him one that he put in his basement. It is always stacked full of containers with concretions from different sites.
'It can sometimes take six months to a year for some to open,' Holm said. 'I go down there almost every other day, and I'm constantly cycling the containers and checking. So that's where the treasure hunt can continue all year round.'
Participants in the Grundy County fossil hunt are still in the freeze-thaw stage for the concretions they found that day.
Jeff Allen, another member of the club, uses half of the freezer in his basement to store his frozen fossils. 'I have a very patient wife,' he chuckled.
'That's the kind of enthusiasm that these collectors have,' Mann said. 'As the Field Museum, we would never be able to do the kind of operation that we're able to accomplish involving local collectors who are doing this work, and having good relationships with them.'
Mann and a colleague have set out to find the missing stage between the anatomies of primitive amphibians and modern ones, hoping the fossils in the 309 million-year-old Mazon Creek hold the answer.
Some modern amphibians have long had body characteristics that make them easily recognizable: frogs with powerful hind legs and salamanders with forelimbs and long tails. Less universally familiar but still peculiar is another kind of amphibian that's still around today, the so-called caecilians, which have long, legless, snake-like bodies and spend most of their lives underground.
'But the thing is, if you go back into the fossil record, you basically see them maintaining the same body plan for about 250 million years. And before that, we have nothing,' said Cal So, a postdoctoral scientist at the museum who specializes in amphibians. 'This time period essentially provides a really good place to look for what some of these early relatives of amphibians looked like. That's one of the biggest mysteries in paleontology — evolutionary biology in general.'
The fossils in Mazon Creek offer a snapshot in time from hundreds of millions of years ago, when high oxygen levels, coal deposits and rapid burial caused many plants and animals, including soft tissues, to be well-preserved.
Mann looked toward the top of the waste pile. 'When you go up, it's like you're going back in time,' he said. 'When you see topology like this, rounded hills are probably spoil piles. And if you dig into these, there's a good chance you're going to find a concretion.'
The Mazon Creek fossil beds include a variety of sites, including local mine spoil piles, no-dig zones like the Mazonia-Braidwood State Fish and Wildlife Area, which requires a permit, and other localities that require sifting through rocks and silt on riverbeds and riverbanks, or bushwhacking through overgrown vegetation.
Fossils in the state are not just limited to this one area. Paleontologists also visit Danville and surrounding areas in east central Illinois, and the Little Egypt region around Cairo in far southern Illinois.
'This geologic history is really all over Illinois. And Mazon Creek could be a gateway into that for people,' Mann said. 'That's really what this locality is about. It's about the intersection between private collectors, amateur paleontologists and professionals, and working together synergistically to unveil the natural history data here — and getting kids hooked on fossils when they're young.'
____
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns

Yahoo

time34 minutes ago

  • Yahoo

Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns

Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool Sign in to access your portfolio

Capturing the melting of glaciers, with data and art
Capturing the melting of glaciers, with data and art

CBS News

time4 hours ago

  • CBS News

Capturing the melting of glaciers, with data and art

In the rugged North Cascade Mountains of Washington State, no one likely knows this glacier better than Mauri Pelto, who says, "My life has been shaped by this ice." For more than 40 years, Pelto, a glaciologist and a professor at Nichols College in Massachusetts, has returned to this remote wilderness. "We got 6,000 measurements on this glacier," he said. Today, the crunch of footsteps in the snow is now rivaled by the sound of melting ice. "It's always melting off," he said. "The crevasses are changing. We can hear the water flowing under our feet." Pelto founded the North Cascade Glacier Climate Project as a grad student in 1984. He vowed to measure these glaciers every summer for 50 years. This is Year 42. In that time the glaciers have changed more than he has, shrinking by 40%. Some have disappeared. Pelto's work has been featured by NASA, and fed into a worldwide glacier database. Of the 47 glaciers he has studied, returning to them year after year, he says 12 are now gone, "nine of them just in the last five years." Climate scientists say warmer summers and drier winters, driven by our burning of fossil fuels, are accelerating the loss. Seven of the 10 worst years for glacier melt worldwide have happened since 2010, according to Climate Central. Or just ask Mauri Pelto where the ice used to be. "Almost 50 feet above my head just a decade ago," he said. Glaciers are Earth's water towers, storing 70% of the freshwater supply, vital for drinking, farming, and the health of many ecosystems. As they melt, sea levels are rising, and coastal flooding is getting worse. During his annual treks to the North Cascades, Pelto has hiked nearly 6,000 miles, and slept 800 nights in a tent. "We got our picture window," he said of the view. "It's also one of those places that's really special to us as a family." His son Ben, daughter Jill, and now his nine-month-old granddaughter Wren have joined him in the field. Jill Pelto has spent 17 summers by her dad's side, but she doesn't just collect data. As the project's art director, she paints it. The data points that she and her dad measure eventually will go into her art. "Data is a story about something in the real world and that story has meaning and emotion," she said. "And that's what I'm trying to bring into my art." Her watercolor paintings are more than just beautiful landscapes; they reveal the science. Look closely and you see a bar graph of glacier decline in the North Cascades. One piece showing temperature rise and ice loss made the cover of Time magazine. Jill said, "I think sometimes when people see data there's this instant reaction, and so it's not like the data is any different in my art, but something about that combination maybe gets people to kind of put down the wall of like, 'Oh, I can't understand this,' or 'You know, this is not something I'm interested in.'" I said, "The average person is not going to read a scientific report, but they will see a painting. And it does impact you in a different way." "Yes, definitely," said Jill. Her art has given her dad a new way to share the story he's been recording for the past 42 years. And it's also changed their relationship: "We do it so seamlessly at this point," Mauri said. "Feels like you're one team out here?" I asked. "Yeah," he replied. Jill added, "This bigger project just means so much to us and has shaped our lives. So, sharing that year after year is beyond special." And now, Mauri Pelto has just eight summers left to fulfill his 50-year promise. Asked what he thinks it will be like to no longer come out to the glaciers, Mauri replied, "I don't know, I can't remember what it was like to not come out here. This landscape has been shaped by ice, and so to understand the landscape and the ice, you really have to walk across it." For more info: Story produced by Chris Spinder, in partnership with Climate Central. Editor: Chris Jolly. See also:

A toxicologist's guide to poison ivy's itch and bee stings' burning pain – 2 examples of nature's chemical warfare
A toxicologist's guide to poison ivy's itch and bee stings' burning pain – 2 examples of nature's chemical warfare

CNN

time5 hours ago

  • CNN

A toxicologist's guide to poison ivy's itch and bee stings' burning pain – 2 examples of nature's chemical warfare

Enjoying the outdoors carries the danger of running into nature's less-friendly side: toxic plants and animals. As toxicologists at the University of Virginia's Blue Ridge Poison Center, we see many patients each year suffering from itchy rashes from poison ivy and stings from wasps or bees. Plants and animals deploy toxins most often in order to defend themselves. Learning how they do that and what happens when the human body is exposed to these substances can offer insights on how to prevent or manage these encounters with nature. The goal is not to scare people away from the outdoors, but to equip them with the knowledge to appreciate these organisms' intricate self-preservation strategies and to protect themselves in return. Whether in a remote state park or on a city playground, most people have encountered poison ivy. This plant is recognizable by its characteristic arrangement of leaves growing in groups of three with edges that vary from smooth to jagged. It can take many forms: a single small plant, a mass of ground cover, a small bush, or a climbing vine reaching many feet up a tree or building. READ: The molecule that makes you itch also stops inflammation Poison ivy – its scientific name is Toxicodendron radicans – and its close relatives poison oak and poison sumac contain an oily substance called urushiol. This chemical is found in every part of the plant: the leaves, roots, stems and even the small white berries it produces in late summer. About 75% of people will develop an allergic reaction on contact with urushiol. Urushiol has antimicrobial properties, and scientists think its job in the poison ivy plant is to protect it from diseases. Because it is so oily, urushiol spreads easily. It can transfer from the plant to your skin, clothes, garden tools or even your pets. Direct plant contact isn't the only risk: If urushiol is on your clothing or a pet's fur and your skin later brushes against it, you can develop the same rash as you'd get from directly touching the plant. Urushiol triggers a delayed allergic reaction. When the oil touches your skin, it binds to skin cells, changing their shape. A molecule called CD1a then clocks urushiol as a foreign substance, prompting the immune system to mount an attack on the cells – hence the rash. READ: Are twins allergic to the same things? The symptoms do not appear instantly; the rash usually appears 12 to 48 hours after exposure. It often starts as redness and itching, then develops into small bumps or fluid-filled blisters. The reaction can be mild or severe, depending on how sensitive you are and how much urushiol got on your skin. The rash itself isn't contagious. Fluid from the blisters doesn't spread it. What spreads the rash to other areas of your body or to others is the urushiol lingering on your skin, clothing, tools or pets. Once the oil is adequately washed away, the rash can't spread to other people or to other areas of your body. If you have touched poison ivy, wash the area as soon as you can with soap and water and change your clothes if possible. After that, the rash will eventually resolve on its own. You can help alleviate symptoms by using a topical steroid or anti-itch cream on the rash. In severe cases, or if the face is affected, patients may require oral steroids to treat the symptoms. Bees and wasps are most active in the late summer. Because of this, we receive more frequent poison center calls about them during this season. Bees and wasps generally sting to defend their hives or nests or to protect themselves from perceived threats. They store venom in their abdominal sacs. When they sting, the venom flows through their stinger and is injected into their target's skin. This venom is a clear, slightly acidic liquid loaded with various active ingredients. For example, it contains enzymes such as phospholipase A2 that break down cell membranes, and peptides such as melittin that cause pain. The venom also contains natural chemicals such as histamine and epinephrine that affect blood vessels and the immune system. Unlike with poison ivy, where the immune system's reaction to the substance causes irritation, with bee and wasp stings it's primarily the substance itself that causes pain – although immune response can still play a role. As soon as the venom enters a person's skin, their body reacts. READ: Are you really allergic to penicillin? A sharp, burning pain comes first as the components of the venom begin to inflict damage, followed by redness and then swelling of the area. Symptoms commonly peak within a few hours and fade within a day. However, some people have stronger reactions with larger areas of swelling that can last for several days. This is because everyone's immune system is slightly different, and some people tend to have stronger reactions than others to foreign substances. In rare cases, the immune system overreacts, releasing large amounts of histamine and other chemicals all at once. Histamine is most often released in response to a foreign substance, causing symptoms of an allergic reaction. This can lead to anaphylaxis, a severe allergic reaction that can make breathing difficult, lower blood pressure and cause airway swelling, and which can quickly become life-threatening. READ: How to manage hay fever in your pets Getting stung multiple times at once can also be life-threatening due to the sheer amount of venom injected, even in people without a bee venom allergy. If you're stung and the stinger is stuck in the skin, it should be removed immediately by the quickest means available. Bee stingers are barbed and can continue to deliver venom for up to a minute. Most bee or wasp stings require only symptomatic treatment, such as an over-the-counter steroid cream or oral antihistamine to reduce itching and swelling. However, people who begin to develop more severe symptoms such as full body hives, vomiting or difficulty breathing should immediately seek emergency care. Anaphylactic reactions require rapid treatment with a medication called epinephrine and close monitoring in the hospital. Christopher P. Holstege is a professor of emergency medicine and pediatrics at University of Virginia. Sandra H. Nixon is a fellow in the Division of Medical Toxicology at University of Virginia.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store